Brett Monia Sells 14,565 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Brett Monia sold 14,565 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $78.41, for a total value of $1,142,041.65. Following the sale, the chief executive officer owned 245,571 shares of the company’s stock, valued at approximately $19,255,222.11. The trade was a 5.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Trading Up 3.6%

Shares of IONS opened at $81.18 on Friday. Ionis Pharmaceuticals, Inc. has a twelve month low of $39.37 and a twelve month high of $86.74. The firm has a market capitalization of $13.42 billion, a P/E ratio of -39.22 and a beta of 0.37. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 2.75. The stock’s fifty day simple moving average is $75.03 and its 200 day simple moving average is $77.36.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.29. The firm had revenue of $246.09 million during the quarter, compared to the consensus estimate of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The firm’s quarterly revenue was up 86.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.93) earnings per share. On average, equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.69 earnings per share for the current year.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jain Global LLC lifted its position in shares of Ionis Pharmaceuticals by 3,037.4% during the third quarter. Jain Global LLC now owns 225,739 shares of the company’s stock worth $14,768,000 after purchasing an additional 218,544 shares in the last quarter. DAVENPORT & Co LLC grew its holdings in Ionis Pharmaceuticals by 248.3% during the 4th quarter. DAVENPORT & Co LLC now owns 217,897 shares of the company’s stock valued at $17,238,000 after purchasing an additional 155,334 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Ionis Pharmaceuticals by 230.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 878,155 shares of the company’s stock valued at $57,449,000 after purchasing an additional 612,362 shares in the last quarter. SG Americas Securities LLC increased its stake in Ionis Pharmaceuticals by 548.7% during the 4th quarter. SG Americas Securities LLC now owns 33,409 shares of the company’s stock worth $2,643,000 after buying an additional 28,259 shares during the period. Finally, DCF Advisers LLC increased its stake in Ionis Pharmaceuticals by 18.2% during the 3rd quarter. DCF Advisers LLC now owns 108,413 shares of the company’s stock worth $7,092,000 after buying an additional 16,663 shares during the period. 93.86% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Ionis received FDA approval expanding TRYNGOLZA to treat severe hypertriglyceridemia, strengthening the drug’s commercial opportunity and making it the first approved therapy for the condition. Article Title
• Positive Sentiment: Ionis announced a licensing deal with Recordati for ex-U.S. rights to zilganersen in Alexander disease, which provides upfront and royalty potential while allowing Ionis to keep U.S. commercialization rights. Article Title
• Positive Sentiment: Leerink Partners raised its price target on Ionis, signaling continued analyst confidence in the company’s pipeline and commercial execution. Article Title
• Neutral Sentiment: HC Wainwright kept a Buy rating but lowered some 2027 EPS estimates, which is a mild headwind but not a major shift in the firm’s overall view. Article Title

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Barclays boosted their target price on Ionis Pharmaceuticals from $106.00 to $115.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Royal Bank Of Canada lifted their price target on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, April 30th. Morgan Stanley boosted their price objective on shares of Ionis Pharmaceuticals from $95.00 to $130.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 21st. Bank of America increased their price objective on shares of Ionis Pharmaceuticals from $100.00 to $111.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Finally, HC Wainwright raised their target price on shares of Ionis Pharmaceuticals from $125.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $102.90.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.